Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
about
Systemic antibiotics for treating diabetic foot infectionsAntibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical woundsCarbapenemsDevelopment of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trialsEpileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations.Pharmacokinetics of ertapenem in healthy young volunteers.Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescentsClinical microdialysis in skin and soft tissues: an update.Pharmacokinetics of intramuscularly administered ertapenemTreatment of bacterial skin and skin structure infections.Ceftaroline in complicated skin and skin-structure infections.Meropenem in the treatment of complicated skin and soft tissue infectionsComparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial.Ertapenem: review of a new carbapenem.Role of linezolid in the treatment of complicated skin and soft tissue infections.Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.The evaluation and treatment of complicated skin and skin structure infections.Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.Pharmacokinetic evaluation of piperacillin-tazobactam.A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot.Diagnostics and treatment of the diabetic foot.From ulcer to infection: an update on clinical practice and adjunctive treatments of diabetic foot ulcers.Interventions in the management of infection in the foot in diabetes: a systematic review.Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections.Microbiota is a primary cause of pathogenesis of chronic wounds.Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam.Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients.Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections.Ertapenem-associated seizures in a peritoneal dialysis patient.Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
P2860
Q24187313-EB56332A-1B90-4A04-A4C4-0A56AFCC25F2Q24202424-6AEA3024-1ACE-43D8-BFEB-A9F29300E0B9Q28286055-6BE04997-2B34-4FCB-B49B-1E24434CA013Q33260093-854F3E2D-E6B5-44D2-A1CB-8DC116196999Q33516983-7D06A025-1107-4A21-AAC7-5A484464E4F0Q34026343-DBC12AE4-C094-4069-ADC6-97A146A0157EQ34141850-CF25A13D-4777-4400-AD05-987E3CCA2E06Q34348830-BED5329B-05E6-4A51-80A7-10984113ACCDQ34752069-48E6861A-8D10-4AC1-9BCC-368F159BED6FQ34938460-C5F9E242-4338-4ED4-916D-9DB15CF38AF4Q35183731-8713933A-10C0-4D91-98FA-3AC4E8DFEF3BQ35715381-91EAAB62-89F0-4B55-B08B-E0250ACE2FF7Q35919254-5EDF09CC-2B77-4FA7-8730-8D4C5F47F573Q35928948-AF1D6301-4313-405F-9204-FB364CFA08C1Q36066200-4F0EFD4F-7538-4093-A78D-919F9075098FQ36505478-FE6435EA-0176-4D4B-8A95-8BDE8853E987Q36663656-9FD37324-14DF-4C5D-B576-E8BDB84106B6Q36719706-6DA83CAB-FA93-4A77-AD9D-CA8BB5DE2964Q36839703-75BDDE03-BF00-4F5A-A35E-C5F8666618AFQ37111836-6EEB4758-81FB-4D3E-A212-B5A5BF545666Q37412959-1F76136A-D0E0-4C8F-9BFA-8BE771A586C8Q37773368-FE805CA7-A166-471B-883C-E0B6E3AA3A51Q37978286-44177C39-9DD5-4047-8337-EFD8801AC68AQ37988404-9A66839B-45F1-404C-BC3D-B144DDB569A3Q38035802-98805E1F-F509-447D-A5F0-732EF1800E70Q38582118-4DB1292F-A3AD-4B11-874F-801063533AAAQ39382608-589392BC-7E78-481F-91B0-0A44419544B2Q40524232-96454B77-0D0C-443D-956E-020E160F4B78Q40546181-0CD07F98-4D57-425F-B662-2F6F55FE1BFDQ40911079-5911C0B0-FFF4-41AD-97EF-2BB5CBE35F50Q42681448-8F2CF82F-2538-4881-A4F8-AC3035FC1A2BQ44098411-690FC074-996E-49A7-84A7-069EBFE05491Q44236347-40280DD9-557D-47A8-84C2-5A8A0B27DDF1Q44635712-7E006168-3877-4281-B6A0-A69E8B42FE32Q44958309-E6D3B405-9137-4572-947E-855F189EA9D2Q45219997-D50EA88F-ADAA-4785-BCA9-09EF8A949D82Q46758156-79EFDFE7-EC61-4173-ACF9-FF5ECAE7C8A9
P2860
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Ertapenem once daily versus pi ...... ouble-blind multicenter study.
@en
Ertapenem once daily versus pi ...... ouble-blind multicenter study.
@nl
type
label
Ertapenem once daily versus pi ...... ouble-blind multicenter study.
@en
Ertapenem once daily versus pi ...... ouble-blind multicenter study.
@nl
prefLabel
Ertapenem once daily versus pi ...... ouble-blind multicenter study.
@en
Ertapenem once daily versus pi ...... ouble-blind multicenter study.
@nl
P2093
P2860
P356
P1476
Ertapenem once daily versus pi ...... ouble-blind multicenter study.
@en
P2093
Andrea McAdams
Christopher Lucasti
Donald R Graham
Gail L Woods
Nora Quintero Perez
Osvaldo Malafaia
Paul Holtom
Richard Gesser
Ronald L Nichols
T Paulette Ceesay
P2860
P304
P356
10.1086/340348
P407
P577
2002-05-09T00:00:00Z